| Date | Title | | | 12/20/16 | ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer’s Disease Psychosis| Data Support Moving Forward With Further Development in
Alzheimer’s Disease Psychosis
Conference Call and Webcast to Be Held Today, December 20, 2016,
at 8:30 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Dec. 20, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced positive
top-line results from its Phase II exploratory study (-019 Study) of
pimavanserin in patients with Alzheimer’s disease psychosis (AD
Psychosis)... |
|  | | 12/01/16 | ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Major Depressive Disorder| SAN DIEGO--(BUSINESS WIRE)--Dec. 1, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
central nervous system (CNS) disorders, today announced the initiation
of CLARITY, a Phase II study to evaluate pimavanserin for adjunctive
treatment in patients with major depressive disorder (MDD) who have an
inadequate response to first-line therapies for clinical depres... |
| | | 11/15/16 | ACADIA Pharmaceuticals Initiates Phase II Trial of Pimavanserin for Adjunctive Treatment in Patients With Negative Symptoms of Schizophrenia| SAN DIEGO--(BUSINESS WIRE)--Nov. 15, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
central nervous system disorders, today announced the initiation of
ADVANCE, a Phase II study to evaluate pimavanserin for adjunctive
treatment in patients with negative symptoms of schizophrenia. Studies
show that about 40 to 50 percent of schizophrenia patients suffer fr... |
| | | 11/07/16 | ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results| NUPLAZID® Net Product Sales Grew to $5.3
Million in the First Full Quarter of Commercialization
Expanding Pimavanserin Clinical Program With Initiation of Studies
for Alzheimer’s Disease Agitation and Adjunctive Treatment of
Schizophrenia
SAN DIEGO--(BUSINESS WIRE)--Nov. 7, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to ad... |
| | | 11/03/16 | ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia| SAN DIEGO--(BUSINESS WIRE)--Nov. 3, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
central nervous system disorders, today announced the initiation of
ENHANCE-1, a Phase III study to evaluate pimavanserin for adjunctive
treatment of schizophrenia in patients with an inadequate response to
current antipsychotic therapy. Current antipsychotics approved for
... |
| | | 11/01/16 | ACADIA Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 7, 2016| ACADIA to Host Conference Call and Webcast on Monday, November 7,
2016, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Nov. 1, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its unaudited financial results for
the third q... |
| | | 10/31/16 | ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation| SAN DIEGO--(BUSINESS WIRE)--Oct. 31, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
central nervous system disorders, today announced the initiation of
SERENE, a Phase II study with pimavanserin for the treatment of
agitation in patients with Alzheimer’s disease (AD Agitation). There is
currently no drug approved by the FDA for the treatment of AD Agitati... |
| | | 10/11/16 | ACADIA Pharmaceuticals Receives California Life Sciences Association’s 2016 Pantheon DiNA Award for Outstanding Therapeutic Product for NUPLAZID™| SAN DIEGO--(BUSINESS WIRE)--Oct. 11, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system (CNS)
disorders, has been awarded the California Life Sciences Association’s
2016 Pantheon DiNA Award for Outstanding Therapeutic Product for
NUPLAZID™ (pimavanserin), the first and only drug approved by the U.... |
| | | 09/20/16 | ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016| SAN DIEGO--(BUSINESS WIRE)--Sep. 20, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the Ladenburg Thalmann 2016
Healthcare Conference on Tuesday, September 27, 2016, at 9:00 a.m.
Eastern Time in New York City.
A live webcast of ... |
| | | 09/19/16 | ACADIA Pharmaceuticals Sponsors National Parkinson Foundation’s Caregiver Summit| ACADIA to Host Booths and Present Posters at the 4th
World Parkinson Congress
SAN DIEGO--(BUSINESS WIRE)--Sep. 19, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system (CNS)
disorders, is sponsoring the National Parkinson Foundation’s (NPF)
Caregiver Summit that will be held today in Port... |
| | | 09/06/16 | ACADIA Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2016| SAN DIEGO--(BUSINESS WIRE)--Sep. 6, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the Morgan Stanley Global
Healthcare Conference on Monday, September 12, 2016, at 12:30 p.m.
Eastern Time in New York City.
A live webcast of ACA... |
| | | 08/24/16 | ACADIA Pharmaceuticals Announces Appointment of Todd S. Young as Executive Vice President, Chief Financial Officer| SAN DIEGO--(BUSINESS WIRE)--Aug. 24, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system (CNS)
disorders, today announced the appointment of Todd S. Young as Executive
Vice President, Chief Financial Officer, effective August 22, 2016. Mr.
Young reports to Steve Davis, ACADIA’s President and Chief ... |
| | | 08/23/16 | ACADIA Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares| SAN DIEGO--(BUSINESS WIRE)--Aug. 23, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that the underwriters for the Company’s previously
announced public offering have fully exercised their option to purchase
an additional 909,090 shares. All 6,969,696 shares sold in the... |
| | | 08/09/16 | ACADIA Pharmaceuticals Prices Public Offering of Common Stock| SAN DIEGO--(BUSINESS WIRE)--Aug. 9, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced the pricing of an underwritten public offering of
6,060,606 shares of its common stock, offered at a price to the public
of $33.00 per share. The gross proceeds from this offering to ACA... |
| | | 08/08/16 | ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock| SAN DIEGO--(BUSINESS WIRE)--Aug. 8, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that it intends to offer and sell, subject to market and
other conditions, $200,000,000 of its common stock in an underwritten
public offering. There can be no assurance as to whether or... |
| | | 08/04/16 | ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results| Quarter highlighted by approval and launch of NUPLAZID™
(pimavanserin) in the United States, the first and only FDA-approved
drug for the treatment of hallucinations and delusions associated with
Parkinson’s disease psychosis
SAN DIEGO--(BUSINESS WIRE)--Aug. 4, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in... |
| | | 07/29/16 | ACADIA Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 4, 2016| ACADIA to Host Conference Call and Webcast on Thursday, August 4,
2016, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Jul. 29, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its unaudited financial results for
the second... |
| | | 06/27/16 | ACADIA Pharmaceuticals Added to Large-Cap Russell 1000 Market Index| SAN DIEGO--(BUSINESS WIRE)--Jun. 27, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it has been added to the Russell 1000 Index,
effective June 27, 2016. The Russell 1000 Index measures the performance
of the large-cap segment of the U.S. equity universe. It is a... |
| | | 06/16/16 | ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 21, 2016| SAN DIEGO--(BUSINESS WIRE)--Jun. 16, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the JMP Securities Life Sciences
Conference on Tuesday, June 21, 2016, at 9:00 a.m. Eastern Time in New
York City.
A live webcast of ACADIA’s pr... |
| | | 06/01/16 | ACADIA Pharmaceuticals to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on June 8, 2016| SAN DIEGO--(BUSINESS WIRE)--Jun. 1, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the Goldman Sachs 37th
Annual Global Healthcare Conference on June 8, 2016, at 3:20 p.m.
Pacific Time in Rancho Palos Verdes, California.
A live ... |
| | | 05/31/16 | ACADIA Pharmaceuticals Announces NUPLAZID™ (pimavanserin) Is Now Available for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis| NUPLAZID is the First and Only FDA-Approved Drug for this
Indication
An Estimated 40 Percent of Parkinson’s Disease Patients Have
Psychosis
SAN DIEGO--(BUSINESS WIRE)--May 31, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced that NUPLAZID™... |
| | | 05/05/16 | ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May 5, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced its unaudited financial results for the first quarter
ended March 31, 2016.
“We are very excited about the recent FDA approval of NUPLAZID™, the
first and only drug approve... |
| | | 05/04/16 | ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11, 2016| SAN DIEGO--(BUSINESS WIRE)--May 4, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the Bank of America Merrill
Lynch Health Care Conference on Wednesday, May 11, 2016, at 2:20 p.m.
Pacific Time in Las Vegas.
A live webcast of ACA... |
| | | 05/02/16 | ACADIA Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 5, 2016| ACADIA to Host Conference Call and Webcast on Thursday, May 5, 2016,
at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--May 2, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its unaudited financial results for
the first quart... |
| | | 04/29/16 | FDA Approves ACADIA Pharmaceuticals’ NUPLAZID™ (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis| U.S. Commercial Launch Planned for June 2016
An Estimated 40 Percent of Parkinson’s Disease Patients Have
Psychosis
Conference Call Scheduled on Monday, May 2 at 8:30 a.m. ET
SAN DIEGO--(BUSINESS WIRE)--Apr. 29, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
... |
| | | 04/06/16 | ACADIA Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016| SAN DIEGO--(BUSINESS WIRE)--Apr. 6, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the 15th Annual
Needham Healthcare Conference on Tuesday, April 12, 2016, at 8:40 a.m.
Eastern Time in New York City.
A live webcast of ACADIA’s ... |
| | | 03/29/16 | FDA Advisory Committee Votes 12 to 2 That Benefits of ACADIA Pharmaceuticals’ NUPLAZID™ (Pimavanserin) for the Treatment of Psychosis Associated with Parkinson’s Disease Outweigh the Risks| SAN DIEGO--(BUSINESS WIRE)--Mar. 29, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced that the U.S. Food and Drug Administration
(FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2
that the benefits of NUPLAZID™ (pimavanserin) for the treatment ... |
| | | 03/29/16 | ACADIA Pharmaceuticals Stock Trading Halted Today| FDA Advisory Committee to Review NUPLAZID™ (Pimavanserin)
New Drug Application for the Treatment of Parkinson’s
Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--Mar. 29, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced that NASDAQ has halted trading of the
... |
| | | 03/01/16 | ACADIA Pharmaceuticals to Present at the Cowen and Company 36th Annual Health Care Conference on March 8, 2016| SAN DIEGO--(BUSINESS WIRE)--Mar. 1, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will present at the Cowen and Company 36th
Annual Health Care Conference on Tuesday, March 8, 2016, at 8:40 a.m.
Eastern Time in Boston.
A live webcast of ACADIA... |
| | | 02/29/16 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015| SAN DIEGO--(BUSINESS WIRE)--Feb. 29, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced its financial results for the fourth quarter and year
ended December 31, 2015.
“2015 was highlighted by the filing of our NUPLAZID™ (pimavanserin) New
Drug Application fo... |
| | | 02/23/16 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016| ACADIA to Host Conference Call and Webcast on Monday, February 29,
2016, at 8:00 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Feb. 23, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its financial results for the fourth
quarter and year... |
| | | 02/03/16 | ACADIA Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference on February 10, 2016| SAN DIEGO--(BUSINESS WIRE)--Feb. 3, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that it will present at the LEERINK Partners 5th
Annual Global Healthcare Conference on Wednesday, February 10, 2016, at
8:00 a.m. Eastern Time in New York City.
A live we... |
| | | 01/29/16 | ACADIA Pharmaceuticals Announces FDA Advisory Committee Meeting to Review NUPLAZID™ (Pimavanserin) for the Treatment of Parkinson’s Disease Psychosis| Advisory Committee Meeting Scheduled for March 29, 2016
SAN DIEGO--(BUSINESS WIRE)--Jan. 29, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced that the Psychopharmacologic Drugs Advisory
Committee of the U.S. Food and Drug Administration (FDA) will review
... |
| | | 01/25/16 | ACADIA Pharmaceuticals Appoints James (Randy) R. Owen, M.D., as Senior Vice President, Clinical Development and Chief Medical Officer| SAN DIEGO--(BUSINESS WIRE)--Jan. 25, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced the appointment of James (Randy) R. Owen,
M.D., as Senior Vice President, Clinical Development and Chief Medical
Officer. Dr. Owen will be responsible for evolving and executing t... |
| | | 01/11/16 | ACADIA Pharmaceuticals Appoints Jim Daly to Board of Directors| SAN DIEGO--(BUSINESS WIRE)--Jan. 11, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced Jim Daly has joined its Board of Directors.
Mr. Daly is a biopharmaceutical executive with 30 years of experience
leading U.S. and global businesses.
“Jim brings ex... |
| | | 01/07/16 | ACADIA Pharmaceuticals to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016| SAN DIEGO--(BUSINESS WIRE)--Jan. 7, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that it will present at the 34th Annual J.P.
Morgan Healthcare Conference on Tuesday, January 12, 2016, at 11:30 a.m.
Pacific Time in San Francisco.
A live webcast of ACAD... |
| | | 01/06/16 | ACADIA Pharmaceuticals Prices Public Offering of Common Stock| SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced the pricing of an underwritten public offering of
10,344,827 shares of its common stock, offered at a price to the public
of $29.00 per share. The gross proceeds from this offering to AC... |
| | | 01/05/16 | ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock| SAN DIEGO--(BUSINESS WIRE)--Jan. 5, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that it intends to offer and sell, subject to market and
other conditions, $300,000,000 of shares of its common stock in an
underwritten public offering. There can be no assurance as to ... |
| |
|
